India Reports Over 3,000 Covid-19 Cases for the Second Consecutive Day

India has continued to report over 3,000 COVID-19 cases for the second consecutive day, with 3,095 new infections recorded in the last 24 hours, as stated by the Union Ministry of Health and Family Welfare on Friday. This marks the highest one-day fresh infections in nearly six months.

Case Positivity Rate and Active Caseload

On Thursday, the country reported 3,016 cases with a case positivity rate of 2.73 percent, which slightly declined to 2.61 percent today. However, the weekly positivity rate rose to 1.91 percent today from 1.71 percent yesterday. The active caseload in the country increased from 13,509 yesterday to 15,208 today, accounting for 0.03 percent of the total number of cases.

Recoveries and Recovery Rate

Within the last 24 hours, 1,390 patients have recovered from the disease, bringing the total number of recoveries to 4,41,69,711. The current recovery rate in the country stands at 98.78 percent.

Vaccination Drive and Testing

According to the Ministry, a total of 220.65 crore vaccine doses have been administered so far under the Nationwide Vaccination Drive, comprising 95.20 crore second doses and 22.86 crore precaution doses. In the past 24 hours, 6,553 COVID vaccine doses were administered. Regarding testing, 1,18,694 tests were conducted in the last 24 hours.

Revised Guidelines

In response to the surge in cases over the past week, the Ministry of Health and Family Welfare has issued revised guidelines for Covid-19 management. These guidelines emphasize certain key points:

Antibiotics should only be used with clinical suspicion of bacterial infection.
Coinfection of COVID-19 with other endemic infections should be considered.
Systemic corticosteroids are not indicated in mild disease.
Key preventive measures include physical distancing, indoor mask use, and hand hygiene.
Symptomatic management, including hydration and temperature monitoring, is crucial.
Immediate medical attention is advised for difficulty breathing, high-grade fever, or severe cough lasting more than 5 days.
Remdesivir may be considered for up to 5 days in moderate or severe cases at high risk of progression.

These guidelines were discussed and prepared in January to ensure effective management of Covid-19 cases.